Navigation Links
Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
Date:8/19/2009

JAMESBURG, N.J., Aug. 19 /PRNewswire/ -- Phytomedics Inc. today announced the publication of the results of a 6 month, Phase 2b clinical trial with an extract of Tripterygium wilfordii Hook F (TwHF) to be developed as PMI-001, in patients with rheumatoid arthritis, in the August 18, 2009 issue of the Annals of Internal Medicine.

In an article entitled "Comparison of Tripterygium wilfordii Hook F versus Sulfasalazine in the Treatment of Rheumatoid," the TwHF extract or thundergod vine was shown to be clinically superior to sulfasalazine (SSZ) using the standard American College of Rheumatology (ACR) criteria with a comparable safety profile. "The results of this clinical trial are very impressive and suggest that a remedy that was first identified in China has real promise to have a major impact on rheumatoid arthritis care world-wide. Although many subjects with rheumatoid arthritis have greatly benefited by the newer biologic agents, there remains an unmet medical need for those people who are unable to receive these agents or have limited access because of financial considerations. For those individuals, as well as many others with rheumatoid arthritis who have active disease despite receiving current therapy, the results of this clinical trial indicate that the extract of Tripterygium wilfordii may provide a new therapeutic alternative. This is very good news for these individuals as well as their families," said Dr Peter Lipsky, Chair of the Phytomedics Scientific Advisory Board. "PMI-001 is an orally absorbable agent that appears to have activity similar to some of the currently available biologic agents. This clinical impact combined with both an acceptable side effect profile and oral dosing make this botanical drug product a unique new therapeutic agent for subjects with rheumatoid arthritis."

Details of the Trial

This randomized, double-blind, active-controlled study was conducted at 11 sites in the U.S., under the auspices of the National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Patients received the TwHF extract 180 mg/day, divided TID (n=60) or SSZ 2 g once daily (n=61) for 24 weeks. The primary endpoint of the study was a 20% improvement in disease activity by ACR criteria (ACR20).

At six months 67.6% of PMI-001-treated patients vs. 36.0% of SSZ-treated patients achieved at least a 20% improvement in disease activity (p=0.02). In the TwHF group, ACR 50 and ACR 70 responses were observed in 54.1% and 37.8% of patients. In the SSZ group, both ACR50 and ACR70 responses were 4.0% (p<0.001 for all comparisons). Significant improvement was seen with all endpoints as early as 2 weeks, including physical function as measured by the HAQ disability score. Patients receiving TwHF had no progression of mean joint space narrowing and erosion scores.

The most common adverse events in both treatment arms were gastrointestinal tract disturbances. Serious adverse events occurred in 3 patients on PMI001 and 7 patients on SSZ. Discontinuations for AEs occurred in 8 (13%) PMI001 patients and 17 (28%) SSZ patients.

Despite recent therapeutic advances, there remains significant unmet medical need for novel alternative therapies for many patients with rheumatoid arthritis. Many of these patients, even after treatment with multiple oral and parenteral drugs, continue to experience uncontrolled pain, joint swelling, fatigue, and impaired physical function. Dr. Laurie Smaldone, President and CEO of Phytomedics Inc. added "We are very pleased with the outcome from this study. We look forward to meeting with FDA to discuss development plans for PMI-001."

About PMI-001

PMI-001 is a novel, oral, disease modifying anti-rheumatic drug currently being developed as a natural pharmaceutical alternative in rheumatoid arthritis therapy. PMI-001 exerts its potent anti-inflammatory and immunosuppressant activities through unique modes of action. Potential applications of this botanical drug candidate beyond rheumatoid arthritis include a wide range of auto-immune disorders including lupus, psoriasis, inflammatory bowel disease and multiple sclerosis.

About Phytomedics

Phytomedics, Inc. is a clinical stage biopharmaceutical company with a novel portfolio of drugs and consumer products solely derived from plant sources. Through this proprietary technology platform, the Company has produced a broad pipeline of lead product candidates, several of which are in clinical development. Founded by Professor Ilya Raskin, Ph.D., presently the company's Chief Scientific Officer, Phytomedics Inc. conducts most of its discovery activities at the Biotech Center of Rutgers University. Phytomedics has supported the development of PMI-001 and in collaboration with Phytomedicinal Greenhouses (PMG), has developed a sophisticated approach to agricultural optimization. This is the first completely standardized botanical preparation of TwHF that is now ready to enter pivotal trials in rheumatoid arthritis.


'/>"/>
SOURCE Phytomedics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson (NYSE: ... Markets Global Healthcare Conference on Tuesday, Feb. 23, at ... Dominic Caruso , Vice President, Finance & Chief Financial ... will represent the Company in a session scheduled at ... --> www.investor.jnj.com . --> This ...
(Date:2/9/2016)... report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - 2019" ... North America continued to lead global anti-bacterial ... into revenues worth US$ 16,907.3 million. North ... , Latin America , Middle-East ... market is inclined towards North America and ...
(Date:2/8/2016)... Cardiac Assist Devices - Medical Devices ... Devices sector report, " Cardiac Assist Devices - ... overview of Cardiac Assist Devices currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... Anxiety of older Americans over steep cost increases of prescription ... decade ago, according to The Senior Citizens League (TSCL). Since last ... with rapidly rising costs. “The implications are chilling, particularly for people with chronic ...
(Date:2/10/2016)... ... February 09, 2016 , ... Traumatic Brian ... of injury may be one of many possible sources: sports, car accidents, falls, ... Course , Mastering Rehab Solutions for the Complexities of Concussions is ...
(Date:2/9/2016)... ... ... February is Heart Awareness Month, and to celebrate Health Quest Chiropractic is ... American Heart Association, New Mexico chapter. , A Heart Rate Variability (HRV) scan is ... Pulse Wave Profiler utilizes a non-invasive technology to determine a heart’s ability to change ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), one ... ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient foundations ... , “Since our Pay It Forward program began, we are proud to have ...
(Date:2/9/2016)... CA (PRWEB) , ... February 09, 2016 , ... Dr. ... home whitening packages. Teeth whitening is among the most popular cosmetic procedures in dentistry ... their whitening needs. This can put them at risk of teeth whitening-related damage. For ...
Breaking Medicine News(10 mins):